Vinca derivatives
AssigneeAMR Technology, Inc.
InventorsIan Scott, Jeffrey Ralph, Matthew Voss
Life of this patent
Estimating the term…
Abstract
The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.
Claims52
A method for inhibiting cell proliferation in mammals comprising:
- administering to a mammal a therapeutically effective amount of the compound of Formula (I) as follows:
- where:
- R1 is:
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- heterocyclyl;
- halogen;
- CN;
- CH(O);
- COR5;
- C(O)NR5R6;
- C(O)NHR5;
- C(O)NH2;
- C(O)NHNH2;
- C(O)NR5NH2;
- C(O)NR5NHR6;
- C(O)NR5NR6R7;
- C(O)NHNHR5;
- C(O)NHNR5R6;
- C(O)NHOH;
- SO2NHNH2;
- SO2NR5NH2;
- SO2NR5NHR6;
- SO2NR5NR6R7;
- SO2NHNHR5;
- SO2NHNR5R6;
- CO2R5;
- SR5;
- SSR5;
- SO2NHR5;
- SO2NR5R6;
- B(OR5)2;
- CF3;
- SH;
- SO2NH2;
- NH2;
- NHR5;
- NHSO2R5;
- NR5R6;
- NHCOR5;
- NR5COR6;
- or
- NR5SO2R6;
- R2=alkyl or CH(O);
- R3=hydrogen, alkyl, or C(O)R5;
- R4=hydrogen or C(O)R5;
- R5, R6 and R7 each are independently alkyl, alkenyl, alkynyl, aryl, or heterocyclyl;
- R8=hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, acyl, or thioalkyl;
- R9=OH and R10=H or R9 and R10 together form a bridging double bond;
- R5 and R6 could form a ring or R6 and R7 could form a ring;
- X=OR5, NR5R6, NHNH2, NHNHC(O)R5, OH;
- NHR5;
- NH2;
- or NHNHC(O)H;
- R4 and X may be linked together with intervening atoms to form a ring;
- R1 and R8 may be linked together;
- or a pharmaceutically acceptable salt thereof, wherein the alkyl and alkenyl groups may be branched, straight, unsubstituted, and/or substituted and wherein the aryl, alkynyl, and heterocyclyl groups are substituted or unsubstituted, with the proviso, that when R8=H, R9=OH, and R10=H, then R1≠Br, I, OH, or OMe.
A method for inhibiting cell proliferation in mammals comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for inhibiting cell proliferation in mammals comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for inhibiting cell proliferation in mammals comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for inhibiting cell proliferation in mammals comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for inhibiting cell proliferation in mammals comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising:
- administering to the mammal a therapeutically effective amount of the compound of Formula (I) as follows:
- where:
- R1 is:
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- heterocyclyl;
- halogen;
- CN;
- CH(O);
- COR5;
- C(O)NR5R6;
- C(O)NHR5;
- C(O)NH2;
- C(O)NHNH2;
- C(O)NR5NH2;
- C(O)NR5NHR6;
- C(O)NR5NR6R7;
- C(O)NHNHR5;
- C(O)NHNR5R6;
- C(O)NHOH;
- SO2NHNH2;
- SO2NR5NH2;
- SO2NR5NHR6;
- SO2NR5NR6R7;
- SO2NHNHR5;
- SO2NHNR5R6;
- CO2R5;
- SR5;
- SSR5;
- SO2NHR5;
- SO2NR5R6;
- B(OR5)2;
- CF3;
- SH;
- SO2NH2;
- NH2;
- NHR5;
- NHSO2R5;
- NR5R6;
- NHCOR5;
- NR5COR6;
- or
- NR5SO2R6;
- R2=alkyl or CH(O);
- R3=hydrogen, alkyl, or C(O)R5;
- R4=hydrogen or C(O)R5;
- R5, R6 and R7 each are independently alkyl, alkenyl, alkynyl, aryl, or heterocyclyl;
- R8=hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, acyl, or thioalkyl;
- R9 OH and R10=H or R9 and R10 together form a bridging double bond;
- R5 and R6 could form a ring or R6 and R7 could form a ring;
- X=OR5, NR5R6, NHNH2, NHNHC(O)R5, OH;
- NHR5;
- NH2;
- or NHNHC(O)H;
- R4 and X may be linked together with intervening atoms to form a ring;
- R1 and R8 may be linked together;
- or a pharmaceutically acceptable salt thereof, wherein the alkyl and alkenyl groups may be branched, straight, unsubstituted, and/or substituted and wherein the aryl, alkynyl, and heterocyclyl groups are substituted or unsubstituted, with the proviso, that when R8=H, R9=OH, and R10=H, then R1≠Br, I, OH, or OMe.
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising:
- administering to a mammal a therapeutically effective amount of a compound having the following chemical formula:
Dependencies are inferred from the claim text.